Induction of DNA breakage in U937 cells by oxazaphosphorines

Folia Biologica

Volumn 58, Issue 1-2, 2010, Pages 15-20

  Mazur, Lidia ^a   Opydo Chanek, Małgorzata ^a   Stojak, Marta ^a   Baran, Jarosław ^b   Niemeyer, Ulf ^c  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c BIELEFELD UNIVERSITY   (Germany)

Author keywords

DNA strand breaks; Oxazaphosphorines; TUNEL technique.; U937 cells

Indexed keywords

ALKYLATING AGENT; BETA D GLUCOSYLISOPHOSPHORAMIDE MUSTARD; BETA-D-GLUCOSYLISOPHOSPHORAMIDE MUSTARD; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE; GLUCOSE; IFOSFAMIDE; MAFOSFAMIDE; PHOSPHORAMIDE MUSTARD;

ARTICLE; CELL STRAIN U937; DNA STRAND BREAKAGE; DRUG EFFECT; HUMAN;

ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; DNA BREAKS; GLUCOSE; HUMANS; IFOSFAMIDE; PHOSPHORAMIDE MUSTARDS; U937 CELLS;

EID: 77953461976     PISSN: 00155497     EISSN: None     Source Type: Journal    
DOI: 10.3409/fb58_1-2.15-20     Document Type: Article

References (31)

1. ADIS INTERNATIONAl LIMITED. 2005. Glufosfamide: Beta-D-Glc-IPM, D-19575. Drug. R & D 6: 49-52.
2. AMMONS W. S., WANG J. W., YANG Z., TIDMARSH G. F., HOFFMAN R. M. 2007. A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia 9: 625-633.
3. BECKER R., RITTER A., EICHHORN U., LIPS J., BERTRAM B., WIESSLER M., ZDZIENICKA M. Z., KAINA B. 2002. Induction of DNA breaks and apoptosis in crosslink-hypersensitive V79 cells by cytostatic drug beta-Dglucosyl-ifosfamide mustard. Br. J. Cancer 86: 130-135.
4. BODY A. V., YULE S. M. 2000. Metabolism and pharmacokinetics of oxazaphosphorines. Clin. Pharmakokinet. 38: 291-304.
5. BRIASOULIS E., JUDSON I., PAVLIDIS N., BEALE P., WANDERS J., GROOT Y., VEERMAN G., SCHUESSLER M., NIEBCH G., SIAMOPOULOS K., TZAMAKOU E., RAMMOU D.,WOLF L.,WALKER R.,HANAUSKE A. 2000. Phase I trial a 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. J. Clin. Oncol. 18: 3535-3544.
6. BRIASOULIS E., PAVLIDIS N., TERRET C., BAUER J., FIEDLER W., SCHÖFFSKI P., RAOUL J. L., HESS D., SELVAIS R., LACOMBE D., BACHMANN P., FUMOLEAU P. 2003. Glufosfamide administered using a 1-hour infusion given as firstline treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur. J. Cancer 39: 2334-2340.
7. BROCK N. 1989. Oxazaphosphorine cytostatics: Pastpresent-future - Seventh Cain Memorial Award Lecture. Cancer Res. 49: 1-7.
8. BRÖKER L. E., GIACCONE G. 2002. The role of new agents in the treatment of non-small cell lung cancer. Eur. J. Cancer 38: 2347-2361.
9. CIULEANU T. E., PAVLOVSKY A. V., BODOKY G., GARIN A. M., LANGMUIR V. K., KROLL S. 2009. A randomized Phase III trial of glufosfamide compared with the best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur. J. Cancer 45: 1589-1596.
10. CHIOREAN E., DRAGOVICH T., HAMM J., LANGMUIR V., KROLL S., JUNG D., COLOWICK A., TIDMARSH G., LOEHRER P. 2008. A phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. Cancer Chemother. Pharmacol. 61: 1019-1026.
11. DARZYNKIEWICZ Z., LI X., BEDNER E. 2001. Use of flow and laser-scanning cytometry in analysis of cell death. (In: Methods in Cell Biology, Schwartz L. M., Ashwell J. D. eds. Academic Press, San Diego CA) 66: 69-109.
12. DOLLNER R., DIETZ A., KOPUN M., HELBIG M., WALLNER F., GRANZOW C. 2004. Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent. Anticancer Res. 24: 2947-2951.
13. ENGEL J., KLENNER T., NIEMEYER U., PETER G., POHL J., SCHÜLER M., SCHUPKE H., VOSS A.,WIESSLER M. 2000. Glufosfamide. Drug. Future 25: 791-794.
14. GIACCONE G., SMIT E. F., DE JONGE M., DANSIN E., BRIASOULIS E., ARDIZZONI A., DOUILLARD J. Y., SPAETH D., LACOMBE D.,BARON B.,BACHMANN P., FUMOLEAU P. 2004. Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer: a phase II trial of the EORTC-New Drug Development Group. Eur. J. Cancer 40: 667-672.
15. GOLDSTEIN M., ROOS W. P.,KAINA B. 2008. Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: Contribution of DNA replication, transcription inhibition and Chk/p53 signaling. Toxicol. Appl. Pharmacol. 229: 20-32.
16. GUIMARAES C. A., LINDEN R. 2004. Programmed cell deaths. Eur. J. Biochem. 271: 1638-1650.
17. KEHRER J. P., BISWAL S. S. 2000. The molecular effect of acrolein. Toxicol. Sci. 57: 6-15.
18. LIANG J., HUANG M., DUAN W., YU X. Q., ZHOU S. 2007. Design of new oxazaphosphorine anticancer drugs. Curr. Pharm. Design 13: 963-978.
19. MAZUR L., OPYDO-CHANEK M., NIEMEYER U. 2008a. Frequency of micronuclei induced in the mouse erythropoietic system by new generetion oxazaphosphorines. Acta Biol. Cracov., Ser. Zool. 50: 5-10.
20. th Euroconference on Apoptosis, September, 6-9, 2008, Bern, Switzerland, Poster No.107.
21. MISIURA K. 2006. Ifosfamide. Metabolic studies, new therapeutic approaches and new analogs. Mini-Rev. Med. Chem. 6: 395-400.
22. MOORE M. J. 1991. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 20: 194-208.
23. POHL J., BERTRAM B., HILGARD P., NOWROUSIAN M. R., STUBEN J., WIESSLER M. 1995. D-19575 - a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport. Cancer Chemother. Pharmacol. J. 35: 364-370.
24. SEKER H., BERTRAM B., BURKLE A., KAINA B., POHL J., KOEPSEL L. H., WIEβLER M. 2000. Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumor therapeutic agent. Br. J. Cancer 82: 629-634.
25. STUBEN J., PORT R., BERTRAM B., BOLLOW U., HULL W. E., SCHAPERM., POHL J.,WIESSLERM. 1996. Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat. Cancer Chemother. Pharmacol. 38: 355-365.
26. STYCZYŃSKI J., WYSOCKI M., DEBSKI R., BALWIERZ W., ROKICKA-MILEWSKA R., MATYSIAK M., BALCERSKA A., KOWALCZYK J., WACHOWIAK J., SOŃTA-JAKIMCZYK D., CHYBICKA A. 2002a. In vitro activity of oxazaphosphorines in childhood acute leukemia: Preliminary report. Acta Biochim. Pol. 49: 221-225.
27. STYCZYŃSKI, WYSOCKI M., KURYLAK A., JURASZEWSKA E., MALINOWSKA I., STANCZAK E., PŁOSZYŃSKA A., STEFANIAK J., MAZUR B., SZCZEPAÑSKI T., RAS M. 2002b. In vitro activity of glufosfamide in childhood acute leukemia. Anticancer Res. 22: 247-250.
28. VAN DEN BENT M. J., GRISOLD W., FRAPPAZ D., STUPP R., DESIR J. P., LESIMPLE T., DITTRICH C., DE JONGE M. J. A., BRANDES A., FRENAY M., CARPENTIER A. F., CHOLLET P., OLIVEIRA J., BARON B., LACOMBE D., SCHUESSLER M., FUMOLEAU P. 2003. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann. Oncol. 14: 1732-1734.
29. VEYHL M., WAGNER K., VOLK C., GORBOULEV V., BAUMGARTEN K., WEBER W. M., SCHAPER M., BARTRAM B., WEISSLER M., KOEPSELL H. 1998. Transport of new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells mediated by Na+-D--glucose cotransporter SAAT1. Proc. Natl. Acad. Sci. USA 95: 2914-2919.
30. ZHANG J., TIAN Q., YUNG CHAN S., CHUEN LI S., ZHOU S., DUAN W., ZHU Y. Z. 2005. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug. Metab. Rev. 37: 611-703.
31. ZHANG J., TIAN Q., YUNG CHAN S., DUAN W., ZHOU S. 2005. Insights into oxazaphosphorine resistance and possible approaches to its circumvention. Drug Resist. Update 8: 271-297.